In this article, the writers will quickly present the general ideas and foundation of bioavailability and bioequivalence (BE), examine the ordinary strategy for BE exhibition, and present case models where novel methodologies have been received by the US FDA for BE showing. Here, 'novel methodologies' incorporate unusual BE considers, just as measurable rules for correlation. All the more explicitly, biowaivers, strategies to show BE for exceptionally factor medications and medication items, and tight remedial file drugs, halfway AUCs as extra measurements for some changed discharge sedate items, techniques to exhibit BE for locally acting gastrointestinal, dermatological, nasal and inward breath items, and non-natural complex medication items, and future points of view in the field of BE appraisal will be talked about. Techniques embraced by different organizations, for example, European Medicines Agency and Health Canada will be contrasted and the FDA approaches when suitable.